TRA CỨU
thông tin biểu ghi
  • Bài trích
  • Ký hiệu PL/XG: 615
    Nhan đề: Khảo sát biến cố bất lợi của Ticagrelor ở bệnh nhân mắc hội chứng mạch vành cấp thông qua chương trình giám sát an toàn hậu mãi /
DDC 615
Tác giả CN Phạm, Nguyễn Vinh
Nhan đề Khảo sát biến cố bất lợi của Ticagrelor ở bệnh nhân mắc hội chứng mạch vành cấp thông qua chương trình giám sát an toàn hậu mãi / Nguyễn Vĩnh Nam, Lương Anh Tùng, Nguyễn Hoàng Anh, Phạm Nguyễn Vinh, Đỗ Quang Huân, Phạm Đức Đạt, Lê Cao Phương Duy, Phạm Mạnh Hùng, Hà Mai Hương, Nguyễn Thị Thu Phượng, Bùi Thị Thu Quỳnh, Lưu Công Thịnh, Âu Dương Ngọc Trân
Tóm tắt To ensure the positive benefit-risk balance of ticagrelor in clinical practice, a post-authorisation safety surveillance was implemented. The tolerability and safety of ticagrelor in real-life settings were evaluated on a cohort of 608 patients with acute coronary syndrome during the one year’s period. A total of 397 AEs were detected, and 30.1 % of the ticagrelor users were found likely disposed to the incidence of adverse events (AE). The possibility of adverse drug reactions (ADRs) rated at 24.4 %. Amongst, only one AE led to hospitalization but without persistent complications. Compared with the period previous to this surveillance, the number of ADR reports increased by 15 times. However, this study recorded a rate of dyspnea quite lower than that previously reported as evidences and data from the WHO global database of individual case safety reports (Vigibase). Maybe, this raised concerns about the ignorance of the risks explainable by baseline diseases of patients. In conclusion, ticagrelor caused no significant ADRs to Vietnamese patients with acute coronary disease within the year of this study. Besides, post-authorisation safety surveillances would be worthy of encouraging in Vietnam to provide additional information to national adverse events database for continous evaluation of drug benefit – risk balance in clinical practice.
Thuật ngữ chủ đề Nghiên cứu kỹ thuật --Việt Nam
Từ khóa tự do Mạch vành cấp
Từ khóa tự do Ticagrelor
Tác giả(bs) CN Đỗ, Quang Huân
Nguồn trích Tạp chí Dược học 2018tr. 3-7 Số: 11
000 00000nab#a2200000ui#4500
00118667
0029
00451A5FAB0-3001-45E4-9A59-B6FE5A2A4E18
005201912051327
008081223s vm| vie
0091 0
039|y20191205132730|zthienvan
082 |a615
100 |aPhạm, Nguyễn Vinh
245 |aKhảo sát biến cố bất lợi của Ticagrelor ở bệnh nhân mắc hội chứng mạch vành cấp thông qua chương trình giám sát an toàn hậu mãi / |cNguyễn Vĩnh Nam, Lương Anh Tùng, Nguyễn Hoàng Anh, Phạm Nguyễn Vinh, Đỗ Quang Huân, Phạm Đức Đạt, Lê Cao Phương Duy, Phạm Mạnh Hùng, Hà Mai Hương, Nguyễn Thị Thu Phượng, Bùi Thị Thu Quỳnh, Lưu Công Thịnh, Âu Dương Ngọc Trân
520 |aTo ensure the positive benefit-risk balance of ticagrelor in clinical practice, a post-authorisation safety surveillance was implemented. The tolerability and safety of ticagrelor in real-life settings were evaluated on a cohort of 608 patients with acute coronary syndrome during the one year’s period. A total of 397 AEs were detected, and 30.1 % of the ticagrelor users were found likely disposed to the incidence of adverse events (AE). The possibility of adverse drug reactions (ADRs) rated at 24.4 %. Amongst, only one AE led to hospitalization but without persistent complications. Compared with the period previous to this surveillance, the number of ADR reports increased by 15 times. However, this study recorded a rate of dyspnea quite lower than that previously reported as evidences and data from the WHO global database of individual case safety reports (Vigibase). Maybe, this raised concerns about the ignorance of the risks explainable by baseline diseases of patients. In conclusion, ticagrelor caused no significant ADRs to Vietnamese patients with acute coronary disease within the year of this study. Besides, post-authorisation safety surveillances would be worthy of encouraging in Vietnam to provide additional information to national adverse events database for continous evaluation of drug benefit – risk balance in clinical practice.
650 |aNghiên cứu kỹ thuật |zViệt Nam
653 |aMạch vành cấp
653 |aTicagrelor
700 |aĐỗ, Quang Huân
773 |tTạp chí Dược học |d2018|gtr. 3-7|i11
890|c1|a0|b0|d5
Không tìm thấy biểu ghi nào